Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Business Model:
Revenue: $10M
Employees: 201-500
Address: 55 Cambridge Pkwy Ste 800E
City: Cambridge
State: MA
Zip: 02142
Country: US
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. They accelerate Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning with seemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology. Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies. They attract, develop, and retain the top scientific, entrepreneurial, and managerial talent in the world.
Contact Phone:
+16178681888
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2007 | Everyday Solutions | Series A | 6.8M |
5/2022 | ProFound Therapeutics | Private Equity Round | 75M |
1/2009 | Celexion | Venture Round | - |
3/2022 | Vesalius Therapeutics | Venture Round | 75M |
11/2013 | Moderna Therapeutics | Venture Round | 110M |
11/2012 | TransMedics | Venture Round | 36M |
7/2016 | Indigo | Series C | 100M |
9/2018 | Indigo | Series E | 250M |
9/2017 | Indigo | Series D | 203M |
1/2020 | Ohana Biosciences | Venture Round | - |
11/2013 | Editas Medicine | Series A | 43M |
5/2009 | Visterra | Seed Round | 3.3M |
3/2004 | Pervasis Therapeutics | Seed Round | 500k |
1/2020 | Ring Therapeutics | Venture Round | 50M |
11/2021 | Alltrna | Venture Round | 50M |
11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
3/2003 | Hypnion | Series B | 47.5M |
1/2003 | VIEO | Series B | 15M |
10/2015 | Janssen Global Services | Venture Round | 32M |
8/2009 | Advanced Electron Beams | Series C | 0 |
2/2005 | Seahorse Bioscience | Series C | 11.5M |
11/2013 | EcoSense Lighting | Venture Round | 15M |
1/2004 | Genomics Collaborative | Venture Round | - |
6/2003 | Ellacoya Networks | Venture Round | 14M |
3/2009 | Seahorse Bioscience | Series D | 6M |
9/2005 | Carbon Design Systems | Series C | 5.3M |
5/2015 | Denali Therapeutics | Series A | 217M |
7/2007 | Tira Wireless | Series D | 5M |
2/2009 | BlackDuck | Series D | 5M |
7/2019 | Valo Health | Series A | 100M |
3/2020 | Sigilon | Series B | 80.3M |
10/2002 | Tira Wireless | Series A | 3M |
2/2016 | Indigo | Series B | 48.5M |
12/2014 | Seres Therapeutics | Series C | 48M |
1/2007 | Ensemble Therapeutics | Venture Round | - |
6/2006 | Zingku | Venture Round | 1M |
6/2018 | Kaleido | Series C | 101M |
1/2004 | Carbon Design Systems | Series B | 10M |
5/2015 | Joule Unlimited, Inc. | Private Equity Round | 40M |
5/2012 | Sesen Bio, Inc. | Series A | 20M |
10/2007 | BDNA | Series D | 0 |
6/2012 | YourBio Health | Series A | 10M |
11/2015 | Evelo Biosciences | Series A | 35M |
1/2006 | Interactive Supercomputing | Series A | 4.5M |
2/2007 | BIND Therapeutics | Series A | 2.5M |
10/2005 | Affinity Express | Venture Round | 3M |
3/2017 | Oasys Water | Series B | 4M |
2/2002 | BG Medicine | Venture Round | 11M |
9/2006 | Carbon Design Systems | Series D | 5M |
6/2011 | MedidaMetrics | Venture Round | 8.5M |
9/2003 | Selventa | Series A | 0 |
10/2009 | LS9 | Series C | 25M |
4/2009 | Avedro | Series B | 10M |
11/2014 | Indigo | Series A | 7.5M |
11/2015 | Codiak Biosciences | Series A | 31M |
1/2003 | Blue Agave Software | Series A | 7M |
1/2006 | T2 Biosystems | Series A | 5.5M |
9/2021 | YourBio Health | Venture Round | 21M |
5/2010 | T2 Biosystems | Series C | 0 |
10/2022 | Cellarity | Series C | 121M |
1/2018 | Inzen Therapeutics | Venture Round | - |
11/2016 | YourBio Health | Series C | 10M |
3/2006 | Helicos BioSciences | Series B | 40M |
12/2019 | Cellarity | Funding Round | 50M |
7/2016 | TransMedics | Private Equity Round | 0 |
12/2002 | Integrated Development Enterprise | Venture Round | 13.3M |
12/2013 | Visterra | Series A | 8.1M |
8/2002 | Flamenco Networks | Series B | 7.4M |
10/2022 | Inari | Series E | 0 |
8/2005 | Intio | Series A | 829k |
3/2017 | CIBO Technologies | Venture Round | 30.3M |
11/2006 | Mascoma | Series B | 30M |
4/2007 | TransMedics | Series D | 0 |
9/2017 | Kaleido BioSciences | Series B | 65M |
11/2007 | BIND Therapeutics | Series B | 16M |
7/2008 | Agios | Series A | 33M |
10/2017 | KSQ Therapeutics | Series B | 76M |
9/2018 | KSQ Therapeutics | Series C | 80M |
9/2020 | Generate Biomedicines | Venture Round | 50M |
5/2021 | Inari | Series D | 0 |
3/2004 | CombinatoRx | Series C | 30M |
5/2021 | Invaio Sciences | Series C | 88.9M |
6/2005 | BlackDuck | Series B | 12M |
2/2015 | EcoSense Lighting | Series C | 25M |
7/2008 | BG Medicine | Series D | 40M |
3/2015 | Red Rock Biofuels | Venture Round | - |
2/2009 | Oasys Water | Series A | 10M |
11/2009 | Receptos | Series A | 25M |
3/2002 | Affinnova | Series A | 4M |
7/2021 | Ring Therapeutics | Series B | 117M |
1/2017 | Incredible Foods | Venture Round | - |
5/2005 | Netuitive | Series C | 5M |
8/2021 | Laronde | Series B | 440M |
1/2021 | Valo Health | Series B | 190M |
8/2020 | Indigo | Series F | 360M |
7/2006 | Mascoma | Series A | 4M |
4/2021 | Repertoire Immune Medicines | Series B | 0 |
8/2002 | NuVox | Private Equity Round | 78.5M |
8/2019 | Inari | Series C | 89M |
11/2018 | Axcella | Series E | 0 |
12/2015 | Rubius Therapeutics | Series A | 25M |
7/2022 | Apriori Bio | Series A | 0 |
10/2013 | Axcella | Series A | 10.8M |
5/2008 | Intio | Convertible Note | 1M |
5/2021 | Laronde | Series A | 50M |
7/2003 | Affinnova | Series B | 6M |
6/2009 | Janssen Global Services | Series A | 15M |
6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
6/2010 | Everyday Solutions | Venture Round | 2.8M |
3/2018 | Foghorn Therapeutics | Venture Round | 50M |
9/2003 | IntelliVid | Series A | 5.5M |
5/2016 | TransMedics | Series F | 0 |
1/2006 | Epitome Biosystems | Venture Round | - |
10/2008 | T2 Biosystems | Series B | 0 |
12/2003 | Blue Agave Software | Series B | 6M |
1/2004 | EngeneOS | Venture Round | - |
3/2005 | Tira Wireless | Series B | 2.5M |
1/2004 | TransMedics | Series B | 27.6M |
4/2008 | VisEn Medical | Series B | 0 |
6/2017 | Rubius Therapeutics | Series B | 120M |
3/2018 | Rubius Therapeutics | Series C | 100M |
12/2011 | Permeon Biologics | Venture Round | 2.5M |
5/2008 | Jinko Solar | Series A | - |
10/2020 | Senda Biosciences | Series A | 88M |
10/2000 | Hypnion | Series A | 10.4M |
3/2017 | Boragen | Series A | 10M |
5/2004 | Ensemble Discovery | Series A | 15M |
11/2007 | Ensemble Discovery | Series B | 15M |
11/2021 | Generate Biomedicines | Series B | 0 |
5/2008 | Selecta Biosciences | Seed Round | 2.5M |
10/2011 | BlackDuck | Series E | 12M |
3/2005 | Tira Wireless | Debt Financing | 2.5M |
4/2013 | Syros Pharmaceuticals | Series A | 30M |
3/2012 | Receptos | Venture Round | 30M |
8/2008 | Quanterix | Series A | 15M |
3/2006 | TransMedics | Series C | 0 |
11/2007 | Novomer | Series A | 6.6M |
8/2009 | Novomer | Series B | 14M |
10/2005 | Integrated Development Enterprise | Venture Round | 1.5M |
7/2017 | Evelo Biosciences | Series B | 50M |
12/2012 | Moderna Therapeutics | Venture Round | 40M |
4/2010 | Selecta Biosciences | Series C | 15M |
12/2013 | Axcella | Series B | - |
10/2017 | Visterra | Series C | 0 |
4/2007 | Netuitive | Series D | 8M |
11/2017 | Codiak Biosciences | Series C | 76.5M |
3/2007 | LS9 | Series A | 5M |
5/2014 | Seres Therapeutics | Series B | 10M |
11/2013 | Seres Therapeutics | Series A | 10.5M |
11/2006 | Tetraphase Pharmaceuticals | Series A | 10M |
3/2004 | Zalicus | Series D | 29.5M |
3/2006 | Tira Wireless | Series C | 13M |
8/2011 | T2 Biosystems | Series D | 0 |
8/2008 | Tetraphase Pharmaceuticals | Series A | 0 |
11/2012 | Tangent Medical Technologies | Series B | 8.6M |
1/2008 | Carbon Design Systems | Series E | 6M |
10/2021 | CIBO Technologies | Series C | 0 |
5/2009 | Carbon Design Systems | Series E | 7.5M |
1/2015 | Tarveda Therapeutics | Series B | 21M |
1/2002 | Renovis | Series B | 0 |
9/2009 | Tetraphase Pharmaceuticals | Series B | 0 |
7/2020 | Omega Therapeutics | Series B | 85M |
10/2007 | Interactive Supercomputing | Series B | 11M |
1/2016 | Codiak Biosciences | Series B | 61M |
5/2011 | YourBio Health | Series A | 4.5M |
1/2006 | Calpurnia Corporation | Series B | 8M |
4/2010 | Joule Unlimited, Inc. | Series B | 30M |
3/2010 | Sesen Bio, Inc. | Series A | 35M |
11/2017 | Repertoire Immune Medicines | Series A | 25M |
10/2007 | LS9 | Series B | 15M |
6/2005 | Brainshark | Series C | 0 |
7/2002 | Continuum Photonics | Series B | 14M |
9/2004 | Ellacoya Networks | Venture Round | 7M |
9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
1/2002 | CombinatoRx | Series B | 40M |
1/2001 | AnVil Informatics, Inc | Series A | - |
9/2006 | Intio | Series B | 2M |
7/2005 | Ellacoya Networks | Series D | 13.5M |
6/2010 | Acceleron Pharma | Venture Round | 10.3M |
12/2005 | Resolvyx Pharmaceuticals | Series A | 17M |
1/1999 | Integrated Development Enterprise | Seed Round | - |
5/2005 | Codon Devices | Series A | 13M |
2/2007 | BlackDuck | Series C | 12M |
1/2012 | Tarveda Therapeutics | Series A | 2.8M |
9/2007 | Kovio | Series D | 19.5M |
7/2004 | BlackDuck | Series A | 5M |
7/2008 | Accuri Cytometers | Series C | 13M |
6/2003 | Nanostream Inc. | Series C | 22M |
5/2008 | Mascoma | Series C | 61M |
3/2021 | Omega Therapeutics | Series C | 126M |
11/2012 | Quanterix | Series C | 0 |
8/2007 | Adnexus | Series C | 15.5M |
6/2011 | Kovio | Venture Round | 0 |
12/2013 | Tarveda Therapeutics | Series B | 21M |
1/2021 | Tessera Therapeutics | Series B | 0 |
10/2006 | Morphotek | Series D | 0 |
9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
3/2013 | T2 Biosystems | Series E | 40M |
7/2004 | ZoomInfo | Series A | 7M |
11/2011 | Agios | Series C | 78M |
2/2012 | Helicos BioSciences | Series A | 27M |
8/2022 | Senda Biosciences | Series C | 123M |
1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
12/2005 | Hypnion | Series B | 0 |
6/2006 | Adnexus | Series B | 27M |
8/2010 | Visterra | Debt Financing | 6M |
10/2014 | Visterra | Series B | 30M |
8/2005 | Pervasis Therapeutics | Series B | 12.4M |
9/2012 | WikiCell Designs | Series A | 10M |
10/2006 | SiCortex | Series B | 21M |
3/2013 | Receptos | Series B | 30M |
8/2006 | Acceleron Pharma | Series B | 30M |
10/2014 | Selecta Biosciences | Private Equity Round | 20M |
8/2014 | YourBio Health | Series B | 16M |
3/2003 | Adnexus | Series A | 13M |
8/2009 | Pervasis Therapeutics | Series C | 17.4M |
6/2010 | BIND Therapeutics | Series C | 12.4M |
11/2012 | Visterra | Series A | 26.1M |
6/2016 | Visterra | Series C | 23.1M |
2/2009 | Selecta Biosciences | Series B | 15.1M |
10/2014 | Syros Pharmaceuticals | Series B | 53M |
4/2004 | Continuum Photonics | Series C | 17.5M |
3/2013 | Janssen Global Services | Venture Round | 13.5M |
9/2004 | SiCortex | Series A | 21M |
4/2011 | Janssen Global Services | Series B | 18.4M |
6/2010 | Tetraphase Pharmaceuticals | Series C | 0 |
6/2009 | Polatis | Venture Round | 8M |
2/2004 | Morphotek | Series C | 26M |
12/2010 | LS9 | Series D | 30M |
12/2006 | Codon Devices | Series B | 20M |
8/2015 | Editas Medicine | Series B | 0 |
1/2005 | Revivio | Series C | 25M |
10/2003 | AVEO Oncology | Series B | 42.7M |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
10/2007 | Acceleron Pharma | Series C | 31M |
2/2017 | Tarveda Therapeutics | Series D | 30M |
3/2010 | TransMedics | Series E | 0 |
1/2019 | Sana Biotechnology | Seed Round | - |
10/2010 | Accuri Cytometers | Series E | 6M |
8/2009 | Accuri Cytometers | Series D | 4M |
4/2022 | Tessera Therapeutics | Series C | 0 |
7/2009 | Kovio | Series E | 20M |
2/2012 | Polatis | Venture Round | 0 |
9/2014 | BlackDuck | Series F | 0 |
6/2020 | Sana Biotechnology | Series A | 700M |
6/2003 | Trusted Network Technologies | Series A | 6M |
8/2004 | Affinnova | Series C | 4.5M |
8/2016 | Denali Therapeutics | Series B | 130M |
10/2019 | Cygnal Therapeutics | Venture Round | 65M |
12/2004 | Pervasis Therapeutics | Series A | 2M |
12/2022 | Montai Health | Series A | 50M |
2/2021 | Cellarity | Series B | 0 |
5/2015 | Axcella | Series C | 39M |
8/2017 | Omega Therapeutics | Series A | 28.4M |
8/2005 | Extraprise | Venture Round | 0 |
12/2017 | Janssen Global Services | Series B | 25M |
1/2008 | Pervasis Therapeutics | Venture Round | 9.8M |
1/2012 | Joule Unlimited, Inc. | Series C | 70M |
1/2020 | Invaio Sciences | Venture Round | - |
3/2013 | Avedro | Series D | 0 |
7/2007 | Ze-gen | Series A | 5.5M |
7/2022 | Apriori Bio | Series A | 0 |
5/2022 | ProFound Therapeutics | Series A | 0 |
4/2022 | Tessera Therapeutics | Series C | 0 |
3/2022 | Vesalius Therapeutics | Series A | 0 |
11/2021 | Generate Biomedicines | Series B | 0 |
11/2021 | Alltrna | Venture Round | 0 |
10/2021 | CIBO Technologies | Series C | 0 |
9/2021 | YourBio Health | Venture Round | 0 |
8/2021 | Laronde | Series B | 0 |
7/2021 | Ring Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|